An open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to human immunodeficiency virus-1

BACKGROUND: Single-tablet regimen (STR) provides a convenient once-daily regimen for the prevention of human immunodeficiency virus (HIV) infection. Here, we investigated the safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as a three-drug, STR fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, An, Xin, Ruolei, Zhang, Hongwei, Dai, Lili, Wu, Ruojun (Esther), Wang, Xi, Li, Aixin, Hua, Wei, Li, Jianwei, Shao, Ying, Gao, Yue, Wang, Zhangli, Ye, Jiangzhu, bu dou re xi ti, Gulimila A, Li, Zaicun, Sun, Lijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944392/
https://www.ncbi.nlm.nih.gov/pubmed/36719359
http://dx.doi.org/10.1097/CM9.0000000000002494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944392/
https://www.ncbi.nlm.nih.gov/pubmed/36719359
http://dx.doi.org/10.1097/CM9.0000000000002494

Ejemplares similares